Table 2. Health state utilities and costs for patients who have incidentally detected pulmonary nodules, are at intermediate risk, and were scheduled for CT surveillance alone.
| Model Parameter | Value | Source |
|---|---|---|
| Health State Utilities | ||
| Age, years | ||
| 50–54 | 0.90 | Fryback 1993 |
| 55–64 | 0.87 | |
| 65–74 | 0.83 | |
| ≥75 | 0.79 | |
| Lung Cancer | ||
| NSCLC | ||
| Local | 0.71 | Black 2014 |
| Regional (ie, Stage 2/3) | 0.67 / 0.65 | |
| Distant | 0.62 | |
| SCLC | 0.62 | Black 2014 |
| Costs* | ||
| AABT | $575 | OncImmune |
| CT | $245 | Black 2014 |
| Diagnostic Follow-up | $5,415 | RBRVS 2016, HCUP-NIS 2014, David 2012, Weiner 2011, Wang Memoli 2012 |
| Bronchoscopy (10% of patients) | $1,553 | |
| CT-TTNA (60% of patients, and includes cost of complications) | $901 | |
| Wedge Resection (30% of patients) | $15,730 | |
| Lung Cancer Treatment | $36,724 | Black 2014 |
ABT, autoantibody test; CT, computed tomography; NSCLC, non-small-cell lung cancer; RBRVS, Resource-Based Relative Value Scale; SCLC, small-cell lung cancer
*Costs expressed in 2016 US dollars